Paris, France-based clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders, Vivet Therapeutics, raised EUR 4.9 million in funding. The company announced the investment on January 31, 2023. It received from the French government to accelerate the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurological disorder. This funding comes from the France Health Innovation Plan 2030’s “Innovations in Biotherapies” framework, specifically the Biotherapies Acceleration Strategy – Bioproduction in Innovative Therapies. Coordinated by the French Health Innovation Agency. The funds will be disbursed over three years and managed by Bpifrance.
Purpose of financing for Vivet Therapeutics
Vivet has plans to use the funds to further develop its gene therapy product VTX-806 as an effective treatment option to stop or reverse disease progression over the long term or potentially cure CTX in patients.
Besides, the company has plans to use the funding for the CrisTauX program. The plan seeks to cover the preclinical research and development activities of VTX-806. It also includes the development of the manufacturing process within medicine, good manufacturing practices and rules, and a clinical study aiming at identifying biomarkers for the effectiveness of treatment in patients under the standard of care. CrisTauX further enables accelerated clinical development of VTX-806 upon completion of the program.
What the company’s official has to add
Gloria Gonzalez, Chief Scientific Officer at Vivet Therapeutics, said, “Our commitment to developing treatment options for metabolic disorders is demonstrated by our lead clinical program, VTX-801, which targets Wilson Disease, alongside a second program, VTX-806, which is in development as a potential treatment option for CTX patients. Our advanced pipeline highlights our ability to provide strong translational support for rare genetic disorders and patients’ needs, notably with the help of the CTX Alliance and the Spanish CTX patient association.”
Anne Douar, Chief Operating Officer at Vivet Therapeutics, further commented, “CTX is a progressive, neurodegenerative disorder that, if left untreated, can lead to debilitating consequences and a poor prognosis affecting a patient’s lifespan. The funding granted as part of France Health Innovation Plan 2030 will enable Vivet to accelerate the development of a transformative and potentially curative treatment with our gene therapy product VTX-806 for patients with CTX.”
About the company
In 2016, founders CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza co-founded the company. A highly experienced management team with deep expertise in developing gene therapies and orphan drugs leads the company. Vivet Therapeutics is a private, clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson’s Disease.j
To explore more such startups, visit Zefyron Startup Database
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
